Analysis of molecular characteristics and prognosis in acute myeloid leukemia patients with AML1/ETO

Objective To analyze the molecular characteristics and prognosis in acute myeloid leukemia patients with AML1/ETO. Methods The clinical data of 63 cases of acute myeloid leukemia(AML)patients with AML1/ETO positive were analyzed retrospectively. 56 cases of AML patients with AML1/ETO negative in the same period were analyzed as control. Characteristics in morphology, immunology, cytogenetics, molecular biology and the clinical effects of treatment were studied and analyzed. Results M2a was 57.12 %(36/63), M2b was 33.33 %(21/63)in AML with AML1/ETO. The percent of initial marrow blasts was 0.46±0.16. The positive rate of CD34, CD13, CD33, CD19, CD7 and CD56 was 67.21 %, 52.46 %, 40.98 %, 63.93 %, 4.92 % and 50.82 %, respectively. The rate of t(8;21)translocation was 82.54 %. There was 4.76 % with additional chromosome abnormality, three cases with EV11and one case with MLL/AT9. The overall CR rate, the relapse rate, the 3-year and the 5-year overall survival rate was 71.43 %, 51.11 %,(43.01±5.31)% and(32.79±3.81)%, respectively. There was no significant difference compared with the control group(P > 0.05). But extramedullary infiltration, the expression of CD56 and additional chromosome abnormality had statistical effects on overall survival(P< 0.05). Conclusions There has unique characteristics in AML with AML1/ETO. The effects of treatment and the prognosis are affected by many factors, so the efficacy and prognosis of AML with AML1/ETO couldnt'just depend on AML1/ETO. Key words: Leukemia, myeloid, acute; AML1/ETO; Prognosis; Multivariate analysis